Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

737.02 -15.30 (-2.03%)
Streaming Delayed Price Updated: 3:39 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
 
Via Benzinga
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
Earnings Outlook For argenx
 
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
The Latest Analyst Ratings for argenx
 
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
The company sells Vyvgart, a treatment for generalized myasthenia gravis. 
Via Investor's Business Daily
Topics Earnings
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review
But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus. 
Via Investor's Business Daily
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
What 20 Analyst Ratings Have To Say About argenx
 
Via Benzinga
What's Going On Pfizer's Subsidiary Biohaven Stock?
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
Why Immunovant Stock Is Bolting Higher Today
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
Via Investor's Business Daily
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
 
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
 
Via Benzinga
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points
These stocks could lead if the market rallies. 
Via Investor's Business Daily
Topics Stocks
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Is Argenx Stock a Buy Now?
Good news keeps rolling in for the biotech. 
Via The Motley Fool
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market
Arista Networks and Dutch biotech Argenx lead this weekend's watch list. 
Via Investor's Business Daily
Topics Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.